These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 27747984)

  • 1. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome.
    Hustoft TN; Hausken T; Ystad SO; Valeur J; Brokstad K; Hatlebakk JG; Lied GA
    Neurogastroenterol Motil; 2017 Apr; 29(4):. PubMed ID: 27747984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial.
    Yan R; Murphy M; Genoni A; Marlow E; Dunican IC; Lo J; Andrew L; Devine A; Christophersen CT
    BMJ Open Gastroenterol; 2020 Aug; 7(1):. PubMed ID: 32816830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial.
    Staudacher HM; Lomer MCE; Farquharson FM; Louis P; Fava F; Franciosi E; Scholz M; Tuohy KM; Lindsay JO; Irving PM; Whelan K
    Gastroenterology; 2017 Oct; 153(4):936-947. PubMed ID: 28625832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet compared with traditional dietary advice for diarrhea-predominant irritable bowel syndrome: a parallel-group, randomized controlled trial with analysis of clinical and microbiological factors associated with patient outcomes.
    Zhang Y; Feng L; Wang X; Fox M; Luo L; Du L; Chen B; Chen X; He H; Zhu S; Hu Z; Chen S; Long Y; Zhu Y; Xu L; Deng Y; Misselwitz B; Lang BM; Yilmaz B; Kim JJ; Owyang C; Dai N
    Am J Clin Nutr; 2021 Jun; 113(6):1531-1545. PubMed ID: 33740048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome.
    Halmos EP; Power VA; Shepherd SJ; Gibson PR; Muir JG
    Gastroenterology; 2014 Jan; 146(1):67-75.e5. PubMed ID: 24076059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal Fermentation in Irritable Bowel Syndrome: Influence of Dietary Restriction of Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols.
    Valeur J; Røseth AG; Knudsen T; Malmstrøm GH; Fiennes JT; Midtvedt T; Berstad A
    Digestion; 2016; 94(1):50-6. PubMed ID: 27487397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal microbiota fingerprint in subjects with irritable bowel syndrome responders to a low FODMAP diet.
    Valdez-Palomares F; Nambo-Venegas R; Uribe-García J; Mendoza-Vargas A; Granados-Portillo O; Meraz-Cruz N; Palacios-González B
    Food Funct; 2021 Apr; 12(7):3206-3218. PubMed ID: 33877245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Effects of a Web-Based Low-FODMAP Diet Versus Probiotic Treatment for Irritable Bowel Syndrome, Including Shotgun Analyses of Microbiota: Randomized, Double-Crossover Clinical Trial.
    Ankersen DV; Weimers P; Bennedsen M; Haaber AB; Fjordside EL; Beber ME; Lieven C; Saboori S; Vad N; Rannem T; Marker D; Paridaens K; Frahm S; Jensen L; Rosager Hansen M; Burisch J; Munkholm P
    J Med Internet Res; 2021 Dec; 23(12):e30291. PubMed ID: 34904950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring Gut Microbiota Composition as an Indicator of Clinical Response to Dietary FODMAP Restriction in Patients with Irritable Bowel Syndrome.
    Valeur J; Småstuen MC; Knudsen T; Lied GA; Røseth AG
    Dig Dis Sci; 2018 Feb; 63(2):429-436. PubMed ID: 29302878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fermentable oligo-, di-, monosaccharides, and polyols (FODMAPs), but not gluten, elicit modest symptoms of irritable bowel syndrome: a double-blind, placebo-controlled, randomized three-way crossover trial.
    Nordin E; Brunius C; Landberg R; Hellström PM
    Am J Clin Nutr; 2022 Feb; 115(2):344-352. PubMed ID: 34617561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of dietary fermentable carbohydrates on a postinflammatory model of irritable bowel syndrome.
    Tuck CJ; Caminero A; Jiménez Vargas NN; Soltys CL; Jaramillo Polanco JO; Lopez Lopez CD; Constante M; Lourenssen SR; Verdu EF; Muir JG; Lomax AE; Reed DE; Vanner SJ
    Neurogastroenterol Motil; 2019 Oct; 31(10):e13675. PubMed ID: 31290223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial.
    Cox SR; Lindsay JO; Fromentin S; Stagg AJ; McCarthy NE; Galleron N; Ibraim SB; Roume H; Levenez F; Pons N; Maziers N; Lomer MC; Ehrlich SD; Irving PM; Whelan K
    Gastroenterology; 2020 Jan; 158(1):176-188.e7. PubMed ID: 31586453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol diet in patients with diarrhea-predominant irritable bowel syndrome: A prospective, randomized trial.
    Goyal O; Batta S; Nohria S; Kishore H; Goyal P; Sehgal R; Sood A
    J Gastroenterol Hepatol; 2021 Aug; 36(8):2107-2115. PubMed ID: 33464683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial.
    Nybacka S; Törnblom H; Josefsson A; Hreinsson JP; Böhn L; Frändemark Å; Weznaver C; Störsrud S; Simrén M
    Lancet Gastroenterol Hepatol; 2024 Jun; 9(6):507-520. PubMed ID: 38643782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels.
    Mazzawi T; Hausken T; Hov JR; Valeur J; Sangnes DA; El-Salhy M; Gilja OH; Hatlebakk JG; Lied GA
    Scand J Gastroenterol; 2019 Jun; 54(6):690-699. PubMed ID: 31190584
    [No Abstract]   [Full Text] [Related]  

  • 16. Gastrointestinal tolerance of low FODMAP oral nutrition supplements in healthy human subjects: a randomized controlled trial.
    Erickson J; Korczak R; Wang Q; Slavin J
    Nutr J; 2017 May; 16(1):35. PubMed ID: 28545589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome.
    Pedersen N; Andersen NN; Végh Z; Jensen L; Ankersen DV; Felding M; Simonsen MH; Burisch J; Munkholm P
    World J Gastroenterol; 2014 Nov; 20(43):16215-26. PubMed ID: 25473176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term effect and adherence of a low fermentable oligosaccharides disaccharides monosaccharides and polyols (FODMAP) diet in patients with irritable bowel syndrome.
    Weynants A; Goossens L; Genetello M; De Looze D; Van Winckel M
    J Hum Nutr Diet; 2020 Apr; 33(2):159-169. PubMed ID: 31637777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial.
    McIntosh K; Reed DE; Schneider T; Dang F; Keshteli AH; De Palma G; Madsen K; Bercik P; Vanner S
    Gut; 2017 Jul; 66(7):1241-1251. PubMed ID: 26976734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome.
    Chumpitazi BP; Cope JL; Hollister EB; Tsai CM; McMeans AR; Luna RA; Versalovic J; Shulman RJ
    Aliment Pharmacol Ther; 2015 Aug; 42(4):418-27. PubMed ID: 26104013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.